<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789035</url>
  </required_header>
  <id_info>
    <org_study_id>1245.9</org_study_id>
    <secondary_id>EudraCT No 2008-000640-14</secondary_id>
    <nct_id>NCT00789035</nct_id>
  </id_info>
  <brief_title>12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients</brief_title>
  <official_title>A Phase IIb, Randomized, Parallel Group Safety, Efficacy, and Pharmacokinetics Study of BI 10773 (5 mg, 10 mg and 25 mg) Administered Orally Once Daily Over 12 Weeks Compared Double Blind to Placebo, as Monotherapy, With an Additional Open-label Metformin Arm in Type 2 Diabetic Patients With Insufficient Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective is to investigate the efficacy, safety and pharmacokinetics of three different
      doses of BI 10773 compared to placebo given for 12 weeks in patients with type 2 diabetes
      mellitus with insufficient glycemic control. In addition an open-label metformin arm will be
      assessed
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change of HbA1c from baseline after 12 weeks of treatment.
Note, adjusted means are presented. For the placebo and empa groups, measured values presented are for the model including only these treatment groups, for the metformin group the measured values presented are for the model including only placebo and metformin groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of FPG From Baseline After 12 Weeks of Treatment</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change of Fasting Plasma Glucose (FPG) from baseline after 12 weeks of treatment. Results presented stem from a repeated measures analysis.
Note, adjusted means are presented. For the placebo and empa groups, measured values presented are for the model including only these treatment groups, for the metformin group the measured values presented are for the model including only placebo and metformin groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HbA1c From Baseline Over Time</measure>
    <time_frame>Baseline and weeks 4, 8 and 12</time_frame>
    <description>Change of HbA1c from baseline over time. Results presented stem from a repeated measures analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Achieve an HbA1c ≤7.0% After 12 Weeks of Treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Results for HbA1c categories at week 12 (Proportion of patients with HbA1c less than equal to 7%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Achieve an HbA1c Lowering of at Least 0.5% After 12 Weeks of Treatment</measure>
    <time_frame>12 weeks</time_frame>
    <description>Results for HbA1c categories at week 12 (Proportion of patients with HbA1c lowered at least 0.5%).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Fasting Plasma Insulin (FPI)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Results for change of FPI from baseline at week 12 based on ANCOVA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostasis Model Assessment Index for Insulin Resistance (HOMA-IR)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>HOMA-IR (to assess insulin resistance) is defined as (FPI x FPG)/22.5. Results based on ANCOVA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostasis Model Assessment Index for Beta Cell Function (HOMA-%B)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>HOMA-%B (to assess insulin beta cell function) is defined as (20 x FPI)/(FPG-3.5). Results are based on ANCOVA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Body Weight After 12 Weeks of Treatment</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Results for change of body weight after 12 weeks of treatment based on ANCOVA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentrations of Empagliflozin in Plasma</measure>
    <time_frame>Days 28, 56 and 84</time_frame>
    <description>Pre-dose (within 30 minutes before dosing) trough concentrations of Empagliflozin in plasma</description>
  </secondary_outcome>
  <enrollment type="Actual">408</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients with a diagnosis of type 2 diabetes mellitus

          -  either treatment-naïve or on a maximum of 1 oral antidiabetic therapy on a stable dose
             for the10 weeks prior to screening

          -  HbA1c ≥6.5 to ≤9.0% and for treatment-naïve patients:HbA1c &gt;7.0 to ≤10.0%

          -  HbA1c &gt;7.0 to ≤10.0% at Visit 2 (start of run-in) for all patients

          -  Age between 18 and 80 years

          -  BMI less than 40 kg/m2

          -  Signed and dated informed consent prior to admission to the study in accordance with
             GCP and local legislation

        Exclusion Criteria:

          1. Myocardial infarction, stroke or TIA within 6 months prior to informed consent

          2. Impaired hepatic function

          3. Renal insufficiency or impaired renal function

          4. Disease of central nervous system, or psychiatric disorders or clinically relevant
             neurologic disorders that may interfere with trial participation

          5. Chronic or clinically relevant acute infections

          6. Current or chronic urogenital tract infection determined by medical history

          7. History of clinically relevant allergy/hypersensitivity

          8. Treatment with glitazones, GLP-1 analogues or insulin within 3 months prior to
             informed consent

          9. Treatment with anti obesity drugs

         10. Current treatment with systemic steroids

         11. Alcohol abuse

         12. Treatment with an investigational drug within 2 months prior to informed consent

         13. known intolerance to metformin

         14. Dehydration

         15. Unstable or acute CHF

         16. Acute or chronic acidosis

         17. Hereditary galactose intolerance

         18. Woman of child bearing potential who are nursing or pregnant or not practicing an
             acceptable method of birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.9.54001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.54002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.54007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.54008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.54009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.54010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.54004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.54003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.54005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salta</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.54006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salta</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.38504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Karlovac</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.38503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krapinske Toplice</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.38506 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osijek</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.38505 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Varazdin</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.38501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.37201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.37202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.37203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Melsungen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Ingbert/Oberwürzbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sulzbach-Rosenberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.82008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.82007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.82009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uijeongbu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.37002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.37001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.40003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.40002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.40004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.40005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Targu-Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.70001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.70002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.70003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.70004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.70005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.70006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.70007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.62002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.62003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.62004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nove Mesto Nad Vahom</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.62001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prievidza</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Härnösand</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.46005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.88605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.88607 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.88604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.88606 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.88601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.88603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.88602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.38003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.38004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.38002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.38001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.9.38005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Croatia</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2008</study_first_submitted>
  <study_first_submitted_qc>November 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 18, 2014</results_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
        </group>
        <group group_id="P2">
          <title>Empagliflozin 5 mg</title>
          <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="P3">
          <title>Empagliflozin 10 mg</title>
          <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="P4">
          <title>Empagliflozin 25 mg</title>
          <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="P5">
          <title>Metformin OL</title>
          <description>Patients were to take a open-label (OL) dose of 500 mg Metformin twice daily for the first 4 weeks. For the remaining 8 weeks, if the fasted blood glucose values were above 110 mg/dL (6.1 mmol/L), the dose was to be increased to 2 x 500 mg tablets twice daily or up to the maximum tolerated.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="81"/>
                <participants group_id="P4" count="82"/>
                <participants group_id="P5" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="81"/>
                <participants group_id="P5" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The treated set (TS) consisting of all randomised patients who were treated with at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
        </group>
        <group group_id="B2">
          <title>Empagliflozin 5 mg</title>
          <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="B3">
          <title>Empagliflozin 10 mg</title>
          <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="B4">
          <title>Empagliflozin 25 mg</title>
          <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="B5">
          <title>Metformin OL</title>
          <description>Patients were to take a dose of 500 mg Metformin (open-label) twice daily for the first 4 weeks. For the remaining 8 weeks, if the fasted blood glucose values were above 110 mg/dL (6.1 mmol/L), the dose was to be increased to 2 x 500 mg tablets twice daily or up to the maximum tolerated.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="81"/>
            <count group_id="B4" value="82"/>
            <count group_id="B5" value="80"/>
            <count group_id="B6" value="406"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="10.2"/>
                    <measurement group_id="B2" value="58.4" spread="9.7"/>
                    <measurement group_id="B3" value="58.2" spread="9.9"/>
                    <measurement group_id="B4" value="56.4" spread="10.3"/>
                    <measurement group_id="B5" value="57.0" spread="8.9"/>
                    <measurement group_id="B6" value="57.5" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment</title>
        <description>Change of HbA1c from baseline after 12 weeks of treatment.
Note, adjusted means are presented. For the placebo and empa groups, measured values presented are for the model including only these treatment groups, for the metformin group the measured values presented are for the model including only placebo and metformin groups.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>The full analysis set (FAS) consists of all randomised patients who were treated with at least 1 dose of study drug and had a baseline measurement of the primary endpoint. Modified last observation carried forward was used as the imputation method (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Metformin OL</title>
            <description>Patients were to take a dose of 500 mg Metformin (open-label) twice daily for the first 4 weeks. For the remaining 8 weeks, if the fasted blood glucose values were above 110 mg/dL (6.1 mmol/L), the dose was to be increased to 2 x 500 mg tablets twice daily or up to the maximum tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment</title>
          <description>Change of HbA1c from baseline after 12 weeks of treatment.
Note, adjusted means are presented. For the placebo and empa groups, measured values presented are for the model including only these treatment groups, for the metformin group the measured values presented are for the model including only placebo and metformin groups.</description>
          <population>The full analysis set (FAS) consists of all randomised patients who were treated with at least 1 dose of study drug and had a baseline measurement of the primary endpoint. Modified last observation carried forward was used as the imputation method (LOCF).</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.09"/>
                    <measurement group_id="O2" value="-0.43" spread="0.09"/>
                    <measurement group_id="O3" value="-0.48" spread="0.09"/>
                    <measurement group_id="O4" value="-0.63" spread="0.09"/>
                    <measurement group_id="O5" value="-0.75" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No formal testing so adjustment for multiple comparisons was not necessary.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for baseline, treatment, number of previous anti-diabetic medications and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.74</ci_lower_limit>
            <ci_upper_limit>-0.29</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 5mg minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No formal testing so adjustment for multiple comparisons was not necessary.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for baseline, treatment, number of previous anti-diabetic medications and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.80</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No formal testing so adjustment for multiple comparisons was not necessary.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Based on ANCOVA with terms for baseline, treatment, number of previous anti-diabetic medications and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>-0.50</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 25mg minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of FPG From Baseline After 12 Weeks of Treatment</title>
        <description>Change of Fasting Plasma Glucose (FPG) from baseline after 12 weeks of treatment. Results presented stem from a repeated measures analysis.
Note, adjusted means are presented. For the placebo and empa groups, measured values presented are for the model including only these treatment groups, for the metformin group the measured values presented are for the model including only placebo and metformin groups.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Metformin OL</title>
            <description>Patients were to take a dose of 500 mg Metformin (open-label) twice daily for the first 4 weeks. For the remaining 8 weeks, if the fasted blood glucose values were above 110 mg/dL (6.1 mmol/L), the dose was to be increased to 2 x 500 mg tablets twice daily or up to the maximum tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of FPG From Baseline After 12 Weeks of Treatment</title>
          <description>Change of Fasting Plasma Glucose (FPG) from baseline after 12 weeks of treatment. Results presented stem from a repeated measures analysis.
Note, adjusted means are presented. For the placebo and empa groups, measured values presented are for the model including only these treatment groups, for the metformin group the measured values presented are for the model including only placebo and metformin groups.</description>
          <population>FAS (LOCF)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="80"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="3.54"/>
                    <measurement group_id="O2" value="-23.26" spread="3.59"/>
                    <measurement group_id="O3" value="-28.92" spread="3.59"/>
                    <measurement group_id="O4" value="-31.08" spread="3.59"/>
                    <measurement group_id="O5" value="-29.96" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of HbA1c From Baseline Over Time</title>
        <description>Change of HbA1c from baseline over time. Results presented stem from a repeated measures analysis.</description>
        <time_frame>Baseline and weeks 4, 8 and 12</time_frame>
        <population>FAS, classical last observation carried forward (CLOCF) was used as the imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Metformin OL</title>
            <description>Patients were to take a dose of 500 mg Metformin (open-label) twice daily for the first 4 weeks. For the remaining 8 weeks, if the fasted blood glucose values were above 110 mg/dL (6.1 mmol/L), the dose was to be increased to 2 x 500 mg tablets twice daily or up to the maximum tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of HbA1c From Baseline Over Time</title>
          <description>Change of HbA1c from baseline over time. Results presented stem from a repeated measures analysis.</description>
          <population>FAS, classical last observation carried forward (CLOCF) was used as the imputation method.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.06"/>
                    <measurement group_id="O2" value="-0.27" spread="0.06"/>
                    <measurement group_id="O3" value="-0.24" spread="0.06"/>
                    <measurement group_id="O4" value="-0.39" spread="0.06"/>
                    <measurement group_id="O5" value="-0.26" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.07"/>
                    <measurement group_id="O2" value="-0.43" spread="0.08"/>
                    <measurement group_id="O3" value="-0.53" spread="0.08"/>
                    <measurement group_id="O4" value="-0.58" spread="0.07"/>
                    <measurement group_id="O5" value="-0.59" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.08"/>
                    <measurement group_id="O2" value="-0.47" spread="0.08"/>
                    <measurement group_id="O3" value="-0.53" spread="0.08"/>
                    <measurement group_id="O4" value="-0.66" spread="0.08"/>
                    <measurement group_id="O5" value="-0.78" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Achieve an HbA1c ≤7.0% After 12 Weeks of Treatment</title>
        <description>Results for HbA1c categories at week 12 (Proportion of patients with HbA1c less than equal to 7%).</description>
        <time_frame>12 weeks</time_frame>
        <population>FAS (CLOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Metformin OL</title>
            <description>Patients were to take a dose of 500 mg Metformin (open-label) twice daily for the first 4 weeks. For the remaining 8 weeks, if the fasted blood glucose values were above 110 mg/dL (6.1 mmol/L), the dose was to be increased to 2 x 500 mg tablets twice daily or up to the maximum tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Achieve an HbA1c ≤7.0% After 12 Weeks of Treatment</title>
          <description>Results for HbA1c categories at week 12 (Proportion of patients with HbA1c less than equal to 7%).</description>
          <population>FAS (CLOCF)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="29.6"/>
                    <measurement group_id="O4" value="45.1"/>
                    <measurement group_id="O5" value="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Achieve an HbA1c Lowering of at Least 0.5% After 12 Weeks of Treatment</title>
        <description>Results for HbA1c categories at week 12 (Proportion of patients with HbA1c lowered at least 0.5%).</description>
        <time_frame>12 weeks</time_frame>
        <population>FAS (CLOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Metformin OL</title>
            <description>Patients were to take a dose of 500 mg Metformin (open-label) twice daily for the first 4 weeks. For the remaining 8 weeks, if the fasted blood glucose values were above 110 mg/dL (6.1 mmol/L), the dose was to be increased to 2 x 500 mg tablets twice daily or up to the maximum tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Achieve an HbA1c Lowering of at Least 0.5% After 12 Weeks of Treatment</title>
          <description>Results for HbA1c categories at week 12 (Proportion of patients with HbA1c lowered at least 0.5%).</description>
          <population>FAS (CLOCF)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6"/>
                    <measurement group_id="O2" value="46.9"/>
                    <measurement group_id="O3" value="59.3"/>
                    <measurement group_id="O4" value="59.8"/>
                    <measurement group_id="O5" value="71.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Fasting Plasma Insulin (FPI)</title>
        <description>Results for change of FPI from baseline at week 12 based on ANCOVA.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS (CLOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Metformin OL</title>
            <description>Patients were to take a dose of 500 mg Metformin (open-label) twice daily for the first 4 weeks. For the remaining 8 weeks, if the fasted blood glucose values were above 110 mg/dL (6.1 mmol/L), the dose was to be increased to 2 x 500 mg tablets twice daily or up to the maximum tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Fasting Plasma Insulin (FPI)</title>
          <description>Results for change of FPI from baseline at week 12 based on ANCOVA.</description>
          <population>FAS (CLOCF)</population>
          <units>mU/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="0.53"/>
                    <measurement group_id="O2" value="-0.90" spread="0.53"/>
                    <measurement group_id="O3" value="-1.02" spread="0.53"/>
                    <measurement group_id="O4" value="-0.90" spread="0.50"/>
                    <measurement group_id="O5" value="-0.01" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Homeostasis Model Assessment Index for Insulin Resistance (HOMA-IR)</title>
        <description>HOMA-IR (to assess insulin resistance) is defined as (FPI x FPG)/22.5. Results based on ANCOVA.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS (CLOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Metformin OL</title>
            <description>Patients were to take a dose of 500 mg Metformin (open-label) twice daily for the first 4 weeks. For the remaining 8 weeks, if the fasted blood glucose values were above 110 mg/dL (6.1 mmol/L), the dose was to be increased to 2 x 500 mg tablets twice daily or up to the maximum tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Homeostasis Model Assessment Index for Insulin Resistance (HOMA-IR)</title>
          <description>HOMA-IR (to assess insulin resistance) is defined as (FPI x FPG)/22.5. Results based on ANCOVA.</description>
          <population>FAS (CLOCF)</population>
          <units>mU/L x mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.26"/>
                    <measurement group_id="O2" value="-0.85" spread="0.27"/>
                    <measurement group_id="O3" value="-0.83" spread="0.26"/>
                    <measurement group_id="O4" value="-0.79" spread="0.25"/>
                    <measurement group_id="O5" value="-0.37" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Homeostasis Model Assessment Index for Beta Cell Function (HOMA-%B)</title>
        <description>HOMA-%B (to assess insulin beta cell function) is defined as (20 x FPI)/(FPG-3.5). Results are based on ANCOVA.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS (CLOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Metformin OL</title>
            <description>Patients were to take a dose of 500 mg Metformin (open-label) twice daily for the first 4 weeks. For the remaining 8 weeks, if the fasted blood glucose values were above 110 mg/dL (6.1 mmol/L), the dose was to be increased to 2 x 500 mg tablets twice daily or up to the maximum tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Homeostasis Model Assessment Index for Beta Cell Function (HOMA-%B)</title>
          <description>HOMA-%B (to assess insulin beta cell function) is defined as (20 x FPI)/(FPG-3.5). Results are based on ANCOVA.</description>
          <population>FAS (CLOCF)</population>
          <units>mU / mmol</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.20" spread="2.56"/>
                    <measurement group_id="O2" value="4.22" spread="2.57"/>
                    <measurement group_id="O3" value="1.09" spread="2.54"/>
                    <measurement group_id="O4" value="2.13" spread="2.43"/>
                    <measurement group_id="O5" value="6.69" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Body Weight After 12 Weeks of Treatment</title>
        <description>Results for change of body weight after 12 weeks of treatment based on ANCOVA.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS (CLOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O5">
            <title>Metformin OL</title>
            <description>Patients were to take a dose of 500 mg Metformin (open-label) twice daily for the first 4 weeks. For the remaining 8 weeks, if the fasted blood glucose values were above 110 mg/dL (6.1 mmol/L), the dose was to be increased to 2 x 500 mg tablets twice daily or up to the maximum tolerated.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Body Weight After 12 Weeks of Treatment</title>
          <description>Results for change of body weight after 12 weeks of treatment based on ANCOVA.</description>
          <population>FAS (CLOCF)</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="82"/>
                <count group_id="O5" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.26"/>
                    <measurement group_id="O2" value="-1.81" spread="0.26"/>
                    <measurement group_id="O3" value="-2.33" spread="0.26"/>
                    <measurement group_id="O4" value="-2.03" spread="0.26"/>
                    <measurement group_id="O5" value="-1.32" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Concentrations of Empagliflozin in Plasma</title>
        <description>Pre-dose (within 30 minutes before dosing) trough concentrations of Empagliflozin in plasma</description>
        <time_frame>Days 28, 56 and 84</time_frame>
        <population>All patients who received at least one dose of Empagliflozin and have some Pharmacokinetic (PK) data.</population>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin 5 mg</title>
            <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O2">
            <title>Empagliflozin 10 mg</title>
            <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>Empagliflozin 25 mg</title>
            <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Concentrations of Empagliflozin in Plasma</title>
          <description>Pre-dose (within 30 minutes before dosing) trough concentrations of Empagliflozin in plasma</description>
          <population>All patients who received at least one dose of Empagliflozin and have some Pharmacokinetic (PK) data.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 28 (N=67, 75, 77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" spread="158"/>
                    <measurement group_id="O2" value="61.7" spread="169"/>
                    <measurement group_id="O3" value="117" spread="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 56 (N=69, 73, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" spread="128"/>
                    <measurement group_id="O2" value="51.6" spread="190"/>
                    <measurement group_id="O3" value="127" spread="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (N=70, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" spread="132"/>
                    <measurement group_id="O2" value="55.3" spread="156"/>
                    <measurement group_id="O3" value="118" spread="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 7 days after last intake of study medication, up to 121 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Patients receive Placebo in tablets matching the Empagliflozin tablets in appearance once daily.</description>
        </group>
        <group group_id="E2">
          <title>Empagliflozin 5 mg</title>
          <description>Patients receive 5 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="E3">
          <title>Empagliflozin 10 mg qd</title>
          <description>Patients receive 10 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="E4">
          <title>Empagliflozin 25 mg qd</title>
          <description>Patients receive 25 mg Empagliflozin in tablets once daily.</description>
        </group>
        <group group_id="E5">
          <title>Metformin OL</title>
          <description>Patients were to take a dose of 500 mg Metformin (open-label) twice daily for the first 4 weeks. For the remaining 8 weeks, if the fasted blood glucose values were above 110 mg/dL (6.1 mmol/L), the dose was to be increased to 2 x 500 mg tablets twice daily or up to the maximum tolerated.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal functional disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

